HIV & AIDS Treatment in Practice
Issue 203
HIV & AIDS Treatment in Practice No. 198
Case Management; Guide for Tutors
1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
These pocket guidelines provide evidence-based guidance on how to reduce the incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people
HIV & AIDS Treatment in Practice No. 188
The purpose of this handbook is to provide guidance to Member States on the practical aspects of maintaining sanitary standards at international borders at ports, airports, and ground crossings (points of entry) as set out in the International Health Regulations (2005). It provides technical advice ...for developing a comprehensive programme for systematic monitoring of disease vectors and integrated vector control at points of entry. This includes standardizing procedures at points of entry and ensuring a sufficient monitoring and response capacity with the necessary infrastructure for surveillance and control of vectors. In addition, this handbook to serves as reference material for port health officers, regulators, port operators, and other competent authorities in charge of implementing the IHR (2005) at points of entry and on conveyances.
more
The Blueprint is intended to guide programming, resource allocation, and commitments to achieve the national objective of a contraceptive prevalence rate (CPR) of 36 percent by 2018.
Economic Issues, Policies and Option for Action
The Global Early Warning – Early Action (EWEA) report on food security and agriculture is developed by the Food and Agriculture Organization of the United Nations (FAO). The report is part of FAO’s EWEA system, which aims to translate forecasts and early warnings into anticipatory action.
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).